Inventor
DING-QUAN QIAN
Inventor
US
Overview
Patents· 14 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds35%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
A61KPreparations for medical, dental or toiletry purposes28%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
12,466,828Bicyclic amines as CDK2 inhibitors202512,247,020Bipyrazole derivatives as JAK inhibitors202512,084,449Imidazotriazines and imidazopyrimidines as kinase inhibitors202411,981,671Bicyclic pyrazolyl amines as CDK2 inhibitors202411,976,073Bicyclic amines as CDK2 inhibitors202411,905,275Bipyrazole derivatives as JAK inhibitors202411,851,426Bicyclic amines as CDK2 inhibitors202311,673,894Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors202311,673,883Heterocyclic compounds as immunomodulators202311,667,635Bicyclic heterocycles as FGFR4 inhibitors202311,591,318Bipyrazole derivatives as JAK inhibitors202311,472,791Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors202211,339,149Heterocyclic compounds as immunomodulators202211,261,191Imidazotriaines and imidazopyrimidines as kinase inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to INCYTE CORP (14)· patent assignee history
2022–2025Patents assigned to INCYTE HOLDINGS CORP (5)· patent assignee history
2022–2025Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| INCYTE CORP | 14 | 2022–2025 |
| INCYTE HOLDINGS CORP | 5 | 2022–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 14 | 2022–2025 |